Pfizer, Genmab’s ADC Tivdak scores full FDA approval in recurrent or metastatic cervical cancer
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.